瑞思迈面临药物替代威胁，股价波动引关注

Core Viewpoint - ResMed (RMD.N) faces potential drug competition from Apnimed's oral obstructive sleep apnea (OSA) medication AD109, which could disrupt its market dominance in the OSA device sector [1] Industry Position - ResMed holds a dominant position in the global OSA device market, capturing 50%-60% market share, primarily relying on CPAP (Continuous Positive Airway Pressure) devices and masks, utilizing a "razor-and-blades" business model [2] Recent Events - Drug Competition Threat: AD109 is an oral combination tablet taken once daily that improves OSA by maintaining upper airway muscle tone. Phase III trials showed a 47% reduction in the apnea-hypopnea index (compared to 7% in the placebo group) with no serious safety issues. If approved by the FDA, it could be available as early as 2027, offering a more convenient treatment option than devices [3] - Patient Compliance Issues: Current CPAP device compliance is only 20%-30% due to noise and discomfort, while the oral medication may attract the nearly 1 billion untreated OSA patients, of whom less than 20% currently receive treatment. If AD109 is successfully launched, it could divert new patients from ResMed, particularly those with mild to moderate OSA, although severe cases may still require device treatment [3] Performance and Operations - Recent Performance Resilience: In Q2 of FY2026 (ending December 31, 2025), ResMed reported an 11% year-over-year revenue increase to $1.4 billion, with a gross margin improvement to 61.8%, reflecting supply chain optimization and product innovation (e.g., AI-driven tools, compact masks) [4] - Strategic Defense: Management highlighted the positive impact of GLP-1 drugs on CPAP compliance during the earnings call and mentioned strategies such as acquisitions or combination therapies (devices + drugs) to counter potential competition. The company maintains strong cash flow (operating cash flow of $340 million in Q2) and low debt levels, indicating a capacity for transformation [4] - Long-term Market Potential: The prevalence of OSA is expected to continue rising (projected 35% increase in the U.S. by 2050), with a large population of untreated patients, suggesting that drugs and devices may coexist rather than completely replace one another [4] Stock Recent Trends - Stock Price Fluctuation: From February 9 to 12, 2026, ResMed's stock price fell from $275.33 to $246.69 (a cumulative decline of 10.4%), partly due to market concerns regarding the potential threat from AD109 [5] - Key Risks: The FDA approval timeline for AD109 (expected in 2026-2027) is a critical variable; if approved, it could lead to a valuation adjustment for ResMed. Additionally, if ResMed fails to innovate or acquire in a timely manner to offset the threat, its long-term market share may be at risk [5]